Literature DB >> 17197751

[A case of chronic myeloid leukemia following TS-1 therapy for advanced gastric cancer].

Masakazu Higuchi1, Hidekazu Nishinaka, Yujiro Yamano.   

Abstract

A 55-year-old woman had received total gastrectomy for advanced gastric cancer in March 2002, and was subsequently treated with adjuvant chemotherapy using oral anti-metabolite TS-1 for 21 months. She was well with no evidence of recurrence of gastric cancer, but leukocytosis was found in June 2005. The analysis of bone marrow revealed that Philadelphia (Ph) chromosome and bcr-abl fusion gene were positive. On the basis of these findings, the chronic phase of secondary chronic myeloid leukemia (CML) was diagnosed. Three months after being started on imatinib therapy, Ph chromosome positive cells disappeared in the bone marrow, and a complete cytogenetic response was achieved. Although CML is rare in secondary leukemia, this is, to our knowledge, the first reported case of therapy-related CML following TS-1 treatment. The present case suggested that imatinib therapy was also effective for secondary CML as well as de novo CML.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17197751

Source DB:  PubMed          Journal:  Gan To Kagaku Ryoho        ISSN: 0385-0684


  3 in total

1.  Chronic myeloid leukemia following colon cancer treatment: A case report and literature review.

Authors:  Mohsen Vakili-Sadeghi; Mohammadhasan Omranpour
Journal:  Caspian J Intern Med       Date:  2013

2.  Chronic myelogenous leukemia after postoperative adjuvant S-1 therapy for rectal cancer: a case report.

Authors:  Masahiro Manabe; Takafumi Nishii; Junya Okita; Johji Nagasaki; Naonori Harada; Yasutaka Aoyama; Takeo Kumura; Tadanobu Ohta; Yoshio Furukawa; Kazuhiro Takeuchi; Atsuko Mugitani
Journal:  Am J Blood Res       Date:  2013-12-18

3.  P190BCR-ABL Chronic Myeloid Leukemia Following a Course of S-1 Plus Oxaliplatin Therapy For Advanced Gastric Adenocarcinoma.

Authors:  Hua Wang; Zhi-Yong Wang; Chun-Hong Xin; Ying-Hui Shang; Rui Jing; Fa-Hong Yan; Si-Zhou Feng
Journal:  Chin Med J (Engl)       Date:  2017-02-20       Impact factor: 2.628

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.